Oliveira-Abreu Klausen, Cipolla-Neto José, Leal-Cardoso Jose Henrique
Laboratório de Eletrofisiologia, Instituto Superior de Ciências Biomédicas, Universidade Estadual do Ceará, Fortaleza 60714-903, CE, Brazil.
Laboratório de Neurobiologia, Instituto de Ciências Biomédicas 1, Universidade de São Paulo, Sao Paulo 05508-000, SP, Brazil.
Int J Mol Sci. 2021 Dec 22;23(1):100. doi: 10.3390/ijms23010100.
Diabetes mellitus (DM) leads to complications, the majority of which are nephropathy, retinopathy, and neuropathy. Redox imbalance and inflammation are important components of the pathophysiology of these complications. Many studies have been conducted to find a specific treatment for these neural complications, and some of them have investigated the therapeutic potential of melatonin (MEL), an anti-inflammatory agent and powerful antioxidant. In the present article, we review studies published over the past 21 years on the therapeutic efficacy of MEL in the treatment of DM-induced neural complications. Reports suggest that there is a real prospect of using MEL as an adjuvant treatment for hypoglycemic agents. However, analysis shows that there is a wide range of approaches regarding the doses used, duration of treatment, and treatment times in relation to the temporal course of DM. This wide range hinders an objective analysis of advances and prospective vision of the paths to be followed for the unequivocal establishment of parameters to be used in an eventual therapeutic validation of MEL in neural complications of DM.
糖尿病(DM)会引发并发症,其中大多数是肾病、视网膜病变和神经病变。氧化还原失衡和炎症是这些并发症病理生理学的重要组成部分。已经开展了许多研究来寻找针对这些神经并发症的特定治疗方法,其中一些研究调查了褪黑素(MEL)的治疗潜力,褪黑素是一种抗炎剂和强大的抗氧化剂。在本文中,我们回顾了过去21年发表的关于MEL治疗糖尿病引起的神经并发症疗效的研究。报告表明,将MEL用作降糖药物的辅助治疗具有切实的前景。然而,分析显示,在与糖尿病病程相关的使用剂量、治疗持续时间和治疗次数方面存在广泛的方法差异。这种广泛的差异阻碍了对进展的客观分析以及对明确确定最终用于MEL治疗糖尿病神经并发症疗效验证的参数所需遵循路径的前瞻性展望。